# Study of Efficacy and Safety of BCD-217 (Anti-CTLA-4 and Anti-PD-1) Followed By BCD-100 (Anti-PD-1) Versus BCD-100 Monotherapy as First-Line Treatment in Patients With Unresectable or Metastatic Melanoma

> **NCT03913923** · PHASE2 · UNKNOWN · sponsor: **Biocad** · enrollment: 117 (actual)

## Conditions studied

- Melanoma
- Melanoma Metastatic

## Interventions

- **BIOLOGICAL:** BCD-217
- **BIOLOGICAL:** BCD-100
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03913923
- **Lead sponsor:** Biocad
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-07-01
- **Primary completion:** 2023-07
- **Final completion:** 2023-12
- **Target enrollment:** 117 (ACTUAL)
- **Last updated:** 2023-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03913923

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03913923, "Study of Efficacy and Safety of BCD-217 (Anti-CTLA-4 and Anti-PD-1) Followed By BCD-100 (Anti-PD-1) Versus BCD-100 Monotherapy as First-Line Treatment in Patients With Unresectable or Metastatic Melanoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03913923. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*